T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$4.01B |
| 2 |
Broadcom
AVGO
|
+$1.49B |
| 3 |
GE Vernova
GEV
|
+$1.19B |
| 4 |
International Paper
IP
|
+$1.05B |
| 5 |
SCHW
Charles Schwab
SCHW
|
+$952M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$2.31B |
| 2 |
Constellation Energy
CEG
|
+$1.94B |
| 3 |
Qualcomm
QCOM
|
+$1.74B |
| 4 |
NVIDIA
NVDA
|
+$1.71B |
| 5 |
Salesforce
CRM
|
+$1.5B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 33.98% |
| 2 | Healthcare | 14.89% |
| 3 | Financials | 10.35% |
| 4 | Consumer Discretionary | 10.11% |
| 5 | Communication Services | 9.23% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2651
SGHC Ltd
SGHC
$6.65B
| $155K | ﹤0.01% |
47,808
+8,696
| +22% | +$29.3K |
|
2652
Aclaris Therapeutics
ACRS
$863M
| $154K | ﹤0.01% |
139,400
+29,633
| +27% | +$34.8K |
|
2653
GrowGeneration
GRWG
$108M
| $154K | ﹤0.01% |
71,385
+2,281
| +3% | +$5.78K |
|
2654
Altimmune
ALT
$560M
| $151K | ﹤0.01% |
22,668
+7,430
| +49% | +$54.8K |
|
2655
Gevo
GEVO
$401M
| $151K | ﹤0.01% |
273,900
-68,036
| -20% | -$45.6K |
|
2656
Kopin
KOPN
$898M
| $151K | ﹤0.01% |
179,700
+37,900
| +27% | +$36.9K |
|
|
NAGE
2657
Niagen Bioscience
NAGE
$241M
| $151K | ﹤0.01% |
55,108
+15,808
| +40% | +$52.9K |
|
|
MPX
2658
DELISTED
Marine Products Corp
MPX
| $149K | ﹤0.01% |
14,668
+1,035
| +8% | +$11.1K |
|
2659
SmartRent
SMRT
$276M
| $148K | ﹤0.01% |
61,814
+8,637
| +16% | +$21.2K |
|
2660
SkinHealth Systems
SKIN
$85.9M
| $147K | ﹤0.01% |
76,447
+1,166
| +2% | +$3.28K |
|
|
HLVX
2661
DELISTED
HilleVax
HLVX
| $146K | ﹤0.01% |
+10,063
| New | +$138K |
|
2662
Zymeworks
ZYME
$1.83B
| $146K | ﹤0.01% |
17,069
+1,405
| +9% | +$12.5K |
|
2663
Farmers National Banc Corp
FMNB
$970M
| $145K | ﹤0.01% |
11,551
+1,120
| +11% | +$13.8K |
|
|
PTVE
2664
DELISTED
Pactiv Evergreen Inc. Common stock
PTVE
| $145K | ﹤0.01% |
12,761
+1,317
| +12% | +$17.5K |
|
2665
Vivid Seats
SEAT
$80.5M
| $144K | ﹤0.01% |
1,248
+183
| +17% | +$19.9K |
|
|
VERV
2666
DELISTED
Verve Therapeutics
VERV
| $144K | ﹤0.01% |
29,314
+3,948
| +16% | +$24.8K |
|
|
AGS
2667
DELISTED
PlayAGS
AGS
| $143K | ﹤0.01% |
12,391
+1,764
| +17% | +$18.2K |
|
2668
GoodRx Holdings
GDRX
$1.27B
| $143K | ﹤0.01% |
18,300
+4,000
| +28% | +$29.6K |
|
2669
NewtekOne
NEWT
$378M
| $143K | ﹤0.01% |
+11,292
| New | +$139K |
|
2670
Omeros
OMER
$1.26B
| $143K | ﹤0.01% |
35,181
| – | – |
|
2671
Organogenesis Holdings
ORGO
$226M
| $143K | ﹤0.01% |
50,951
| – | – |
|
2672
Mission Produce
AVO
$1.15B
| $142K | ﹤0.01% |
14,317
+385
| +3% | +$4.4K |
|
2673
Pixelworks
PXLW
$45.7M
| $142K | ﹤0.01% |
12,033
+2,741
| +29% | +$48.7K |
|
|
OSG
2674
DELISTED
Overseas Shipholding Group Inc.
OSG
| $142K | ﹤0.01% |
16,641
-379
| -2% | -$2.75K |
|
|
HONE
2675
DELISTED
HarborOne Bancorp
HONE
| $140K | ﹤0.01% |
12,525
+744
| +6% | +$7.63K |
|
Similar funds
T. Rowe Price Associates's Q2 2024 Portfolio in Review
As of Q2 2024, T. Rowe Price Associates held 3,089 positions worth $836B, up 2.4% from $816B the previous quarter. Its ten largest holdings account for 36% of the portfolio.
T. Rowe Price Associates's Q2 2024 filing shows 135 new, 1,850 increased, 836 reduced and 113 closed positions. Its largest new stake was Tempus AI: 5,227,120 shares worth $183M. The largest sale was Microsoft, an estimated $2.31B.
By sector, the portfolio is most concentrated in Technology at 34% of assets, up from 32% a quarter earlier, followed by Healthcare and Financials.
- T. Rowe Price Associates's largest Q2 2024 buy was Tempus AI: 5,227,120 shares worth $183M.
- T. Rowe Price Associates added most to Apple in Q2 2024, an estimated $4.01B increase.
- T. Rowe Price Associates's biggest Q2 2024 reduction was Microsoft, cutting an estimated $2.31B.
- T. Rowe Price Associates fully exited Pioneer Natural Resource Co. in Q2 2024, selling an estimated $570M.
- T. Rowe Price Associates's ten largest holdings make up 36% of its $836B portfolio in Q2 2024.
- T. Rowe Price Associates opened 135 new positions and closed 113 in Q2 2024.
- T. Rowe Price Associates's portfolio value rose 2.4% quarter-over-quarter to $836B.
Based on T. Rowe Price Associates's 13F filing for Q2 2024, filed 14 Aug 2024.